TY - JOUR
T1 - Prostate Cancer Progression
T2 - Aspirin Induces Toxicity in Prostate Cancer Cell
AU - Ogundiya, Olaniyi
AU - Whiteland, Helen
AU - Shah, U. K.
AU - Bodger, O.
AU - Verma, J.
AU - Haboubi, H.
AU - Rees, B.
AU - Kynaston, H.
AU - Doak, S.
PY - 2017/11/30
Y1 - 2017/11/30
N2 - Introduction: Aspirin has shown a great promise in the management of cancer. Evidence from colorectal cancer studies suggests that the antitumor properties of aspirin are due to the direct inhibition of cyclooxygenase-2 (COX-2) activity. Such evidence are lacking in prostate cancer. In our previous study, we reported that prostate cancer cell express high levels of COX-2. Therefore, we evaluated the role of aspirin in prostate cancer progression.
Aim: To assess the toxicity of aspirin and it active metabolite, sodium salicylate in prostate cell.
Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. Relative population doubling (RPD) was applied to provide a quantitative measure of cell growth, death and cytostasis.
Result: We observed that sodium salicylate was most potent in PC-3 cells, the most aggressive cell line and least potent in PNT2 (normal prostate cell). LC50 values were 8.5mM, 9.2mM and 13.2mM for PC3, DU145 and PNT2 respectively.
With aspirin, prostatic cancer cell lines (PC-3, DU-145) showed highly significant toxicity response compared to normal prostate cell (PNT2) from 6mM (p<0.0001).
Conclusion: This study provides evidence that aspirin has a role in prostate cancer progression
AB - Introduction: Aspirin has shown a great promise in the management of cancer. Evidence from colorectal cancer studies suggests that the antitumor properties of aspirin are due to the direct inhibition of cyclooxygenase-2 (COX-2) activity. Such evidence are lacking in prostate cancer. In our previous study, we reported that prostate cancer cell express high levels of COX-2. Therefore, we evaluated the role of aspirin in prostate cancer progression.
Aim: To assess the toxicity of aspirin and it active metabolite, sodium salicylate in prostate cell.
Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. Relative population doubling (RPD) was applied to provide a quantitative measure of cell growth, death and cytostasis.
Result: We observed that sodium salicylate was most potent in PC-3 cells, the most aggressive cell line and least potent in PNT2 (normal prostate cell). LC50 values were 8.5mM, 9.2mM and 13.2mM for PC3, DU145 and PNT2 respectively.
With aspirin, prostatic cancer cell lines (PC-3, DU-145) showed highly significant toxicity response compared to normal prostate cell (PNT2) from 6mM (p<0.0001).
Conclusion: This study provides evidence that aspirin has a role in prostate cancer progression
U2 - 10.1016/j.ijsu.2017.08.084
DO - 10.1016/j.ijsu.2017.08.084
M3 - Article
SN - 1743-9191
VL - 47
SP - S13
JO - International Journal of Surgery
JF - International Journal of Surgery
IS - S1
ER -
